Eloxx Pharmaceuticals (NASDAQ:ELOX) Upgraded to Strong-Buy at Lucid Cap Mkts

Lucid Cap Mkts upgraded shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) to a strong-buy rating in a research note published on Thursday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Lifesci Capital started coverage on shares of Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 price objective for the company. Weiss Ratings assumed coverage on Eloxx Pharmaceuticals in a research note on Friday, August 14th. They issued a “sell (d)” rating on the stock. Wall Street Zen upgraded Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. Finally, Guggenheim initiated coverage on Eloxx Pharmaceuticals in a research report on Monday, July 20th. They set a “buy” rating and a $43.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eloxx Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $41.50.

Eloxx Pharmaceuticals Price Performance

NASDAQ:ELOX opened at $20.98 on Thursday. The stock has a market cap of $84.76 million, a P/E ratio of -13.62 and a beta of -1,864.08. The company’s 50-day simple moving average is $14.32. Eloxx Pharmaceuticals has a twelve month low of $8.20 and a twelve month high of $23.40.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.